ViaCell, which is developing cellular therapies for the treatment of cancer, genetic and cardiac diseases, and infertility, announced pricing terms for its upcoming IPO on Monday. The company will offer 7.5 million shares within a proposed price range of $7 to $9, for an estimated market cap of $289 million. CS First Boston and UBS Investment Bank will act as joint book runners on the deal. The company has filed to be traded on the NASDAQ under the ticker VIAC.
